Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study

BACKGROUND: Patients with interstitial lung disease (ILD) are at high risk of severe COVID-19 infection. Additionally, their anti-inflammatory and antifibrotic treatment may cause immunosuppression. Nevertheless, their ability to mount an adequate immune response to messenger RNA SARS-CoV-2 vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales: Pertzov, Barak, Shmueli, Einat, Ben Zvi, Haim, Massarweh, Amir, Barkan, Tamar, Ness, Asaf, Shostak, Yael, Freidkin, Lev, Shtraichman, Osnat, Kramer, Mordechai R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433517/
https://www.ncbi.nlm.nih.gov/pubmed/36045374
http://dx.doi.org/10.1186/s12931-022-02155-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433517/
https://www.ncbi.nlm.nih.gov/pubmed/36045374
http://dx.doi.org/10.1186/s12931-022-02155-x

Ejemplares similares